Compounds > gp 683
Page last updated: 2024-12-10

gp 683

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID5311109
CHEMBL ID100421
SCHEMBL ID6684942
MeSH IDM0280884

Synonyms (9)

Synonym
CHEMBL100421 ,
gp683
gp836
2-methyl-5-(5-phenyl-4-phenylamino-pyrrolo[2,3-d]pyrimidin-7-yl)-tetrahydro-furan-3,4-diol
(2r,3s,4r,5r)-2-methyl-5-(5-phenyl-4-phenylamino-pyrrolo[2,3-d]pyrimidin-7-yl)-tetrahydro-furan-3,4-diol
5-phenyl-4-(phenylamino)-7-(5-deoxy-beta-d-ribofuranosyl)-pyrrolo[2,3-d]pyrimidine
bdbm50090887
(2r,3r,4s,5r)-2-(4-anilino-5-phenylpyrrolo[2,3-d]pyrimidin-7-yl)-5-methyloxolane-3,4-diol
SCHEMBL6684942

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" Also reported is the characterization of a lead AKI, 19d (GP3966), an orally bioavailable compound (F% = 60% in dog) which exhibits broad-spectrum analgesic activities (ED50 < or = 4 mg/kg, per os) that are reversible with an adenosine receptor antagonist (theophylline)."( Adenosine kinase inhibitors. 5. Synthesis, enzyme inhibition, and analgesic activity of diaryl-erythro-furanosyltubercidin analogues.
Boyer, SH; Erion, MD; Gomez-Galeno, JE; Kopcho, J; Matelich, MC; Mendonca, R; Nagahisa, A; Nakane, M; Ollis, K; Solbach, J; Tsuchiya, M; Ugarkar, BG; Wiesner, JB, 2005)		0.33
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Adenosine kinaseHomo sapiens (human)IC50 (µMol)0.00050.00050.605210.0000AID1628630; AID240636; AID255140; AID256903; AID33987
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (7)

Processvia Protein(s)Taxonomy
purine ribonucleoside salvageAdenosine kinaseHomo sapiens (human)
dATP biosynthetic processAdenosine kinaseHomo sapiens (human)
ribonucleoside monophosphate biosynthetic processAdenosine kinaseHomo sapiens (human)
GMP salvageAdenosine kinaseHomo sapiens (human)
AMP salvageAdenosine kinaseHomo sapiens (human)
dAMP salvageAdenosine kinaseHomo sapiens (human)
purine nucleobase metabolic processAdenosine kinaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (5)

Processvia Protein(s)Taxonomy
RNA bindingAdenosine kinaseHomo sapiens (human)
deoxyadenosine kinase activityAdenosine kinaseHomo sapiens (human)
ATP bindingAdenosine kinaseHomo sapiens (human)
metal ion bindingAdenosine kinaseHomo sapiens (human)
adenosine kinase activityAdenosine kinaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (4)

Processvia Protein(s)Taxonomy
nucleoplasmAdenosine kinaseHomo sapiens (human)
cytosolAdenosine kinaseHomo sapiens (human)
plasma membraneAdenosine kinaseHomo sapiens (human)
nucleusAdenosine kinaseHomo sapiens (human)
cytosolAdenosine kinaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (9)

Assay IDTitleYearJournalArticle
AID184562Tested for inhibition of MES-induced seizures in rat after ip administration of 5 mg/kg2000Journal of medicinal chemistry, Jul-27, Volume: 43, Issue:15
Adenosine kinase inhibitors. 2. Synthesis, enzyme inhibition, and antiseizure activity of diaryltubercidin analogues.
AID255140Inhibitory concentration against human recombinant adenosine kinase using [14C]AMP as radioligand2005Journal of medicinal chemistry, Oct-06, Volume: 48, Issue:20
Adenosine kinase inhibitors. 5. Synthesis, enzyme inhibition, and analgesic activity of diaryl-erythro-furanosyltubercidin analogues.
AID1628630Inhibition of human adenosine kinase assessed as reduction in conversion of adenosine to AMP2016Journal of medicinal chemistry, 07-28, Volume: 59, Issue:14
South (S)- and North (N)-Methanocarba-7-Deazaadenosine Analogues as Inhibitors of Human Adenosine Kinase.
AID176255Intraperitoneal effective dose required for inhibition of MES-induced seizures in rat2000Journal of medicinal chemistry, Jul-27, Volume: 43, Issue:15
Adenosine kinase inhibitors. 2. Synthesis, enzyme inhibition, and antiseizure activity of diaryltubercidin analogues.
AID256905Solubility in water at pH 7.42005Journal of medicinal chemistry, Dec-01, Volume: 48, Issue:24
Adenosine kinase inhibitors. 6. Synthesis, water solubility, and antinociceptive activity of 5-phenyl-7-(5-deoxy-beta-D-ribofuranosyl)pyrrolo[2,3-d]pyrimidines substituted at C4 with glycinamides and related compounds.
AID33987Inhibition of recombinant human adenosine kinase2000Journal of medicinal chemistry, Jul-27, Volume: 43, Issue:15
Adenosine kinase inhibitors. 2. Synthesis, enzyme inhibition, and antiseizure activity of diaryltubercidin analogues.
AID240636Inhibitory activity against Human Recombinant Adenosine Kinase2005Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
Adenosine kinase inhibitors. 4. 6,8-Disubstituted purine nucleoside derivatives. Synthesis, conformation, and enzyme inhibition.
AID256388Percent inhibition of the licking and biting behavior in response to formalin injection at a dose of 20 mg/Kg when given orally in rat by formalin paw assay; (n=6)2005Journal of medicinal chemistry, Oct-06, Volume: 48, Issue:20
Adenosine kinase inhibitors. 5. Synthesis, enzyme inhibition, and analgesic activity of diaryl-erythro-furanosyltubercidin analogues.
AID256903Inhibitory activity against recombinant human adenosine kinase2005Journal of medicinal chemistry, Dec-01, Volume: 48, Issue:24
Adenosine kinase inhibitors. 6. Synthesis, water solubility, and antinociceptive activity of 5-phenyl-7-(5-deoxy-beta-D-ribofuranosyl)pyrrolo[2,3-d]pyrimidines substituted at C4 with glycinamides and related compounds.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (80.00)29.6817
2010's1 (20.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.87

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.87 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.66 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.87)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
abt 702
[no description available]		2.1310bipyridines
5-iodotubercidin
7-iodotubercidin: inhibits Toxoplasma gondii adenosine kinase		2.4620organoiodine compound
5'-amino-5'-deoxyadenosine
[no description available]		2.0210
ConditionIndicatedRelationship StrengthStudiesTrials
Absence Seizure
[description not available]		0210
Seizures
Clinical or subclinical disturbances of cortical function due to a sudden, abnormal, excessive, and disorganized discharge of brain cells. Clinical manifestations include abnormal motor, sensory and psychic phenomena. Recurrent seizures are usually referred to as EPILEPSY or seizure disorder.		0210